Merck Adds Harpoon Candidate To Its Daiichi Sankyo Partnership…

As of this morning, this is immaterial from a financial point of view, but it makes sense -- as a continued integration of Harpoon rolls forward.

In any event, here's the latest, from SA:

. . .Merck announced Tuesday that it has added another experimental therapy to the Sankyo venture / partnership, which targeted a class of cancer drugs known as antibody-drug conjugates.

[A candidate acquired in the Harpoon purchase is being added] to the three investigational DXd ADCs initially targeted. . . the [partners] will jointly develop and commercialize MK-6070, a T-cell engager. . . .

The companies will share the R&D and commercialization costs for MK-6070 as well as its worldwide profits, except in Japan, where Merck retains exclusive rights. . . .

Designed to target a compound found in small cell lung cancer (SCLC) and neuroendocrine tumors, MK-6070 is currently undergoing a Phase 1/2 clinical trial. . . .

Now you know. It's Veep Day, but im afraid my favorite (AZ Sen. Kelly) won't be the chosen one. So it goes.

नमस्ते